GWSA
ADMA icon

Global Wealth Strategies & Associates’s ADMA Biologics ADMA Stock Holding History

Global Wealth Strategies & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$45 – 103
2026
Q1 		$45 Hold
5
– – ﹤0.01% 531
2025
Q4 		$91 Hold
5
– – ﹤0.01% 527
2025
Q3 		$73 Hold
5
– – ﹤0.01% 478
2025
Q2 		$91 Buy
+5
New +$102 ﹤0.01% 368

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Global Wealth Strategies & Associates's ADMA Position: Q2 2026 in Review

Global Wealth Strategies & Associates sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 5 shares — an estimated $45 sold.

Global Wealth Strategies & Associates first reported a position in ADMA in Q2 2025 and held it in 4 quarters. The position peaked at $91 in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Global Wealth Strategies & Associates reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 5 ADMA Biologics shares in Q2 2026, an estimated $45.
  • Global Wealth Strategies & Associates first reported a position in ADMA Biologics in Q2 2025 and held it in 4 quarters.
  • Global Wealth Strategies & Associates's ADMA Biologics position peaked at $91 in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Global Wealth Strategies & Associates's 13F filing for Q2 2026, filed 1 Jul 2026.